IMCR

Business Context and Reporting Period

Company: Immunocore Holdings Plc
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Immunocore is a commercial-stage biotechnology company developing immunomodulating medicines using its proprietary ImmTAX platform. Its lead product, KIMMTRAK (tebentafusp), is approved for metastatic uveal melanoma in 39 countries and commercially launched in over 30. The company operates in a single segment: immunotherapies.

Key Financial Metrics

Revenue Breakdown (Q1 2026): United States ($67.4M), Europe ($34.4M), International ($4.8M).
Expenses: R&D ($61.1M), SG&A ($37.9M), Cost of Revenue ($0.4M).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13.6% year-over-year, driven by a 19.1% increase in U.S. sales and a 4.9% increase in European sales.
• Profitability: The company reported a net income of $13.0M compared to $5.0M in the prior year, resulting in a positive operating income of $7.3M versus a loss of $3.6M previously.
• Cash Flow: Operating cash flow turned negative, using $13.8M compared to providing $0.4M in Q1 2025. This was primarily due to increases in accounts receivable and prepaid expenses.
• R&D Expenses: Increased 8.2% to $61.1M, largely due to higher costs for PRAME programs (PRISM-MEL-301 Phase 3 trial) and increased internal employee-related costs.
• Foreign Currency: Recorded a foreign currency gain of $3.8M, up from $3.1M, due to favorable exchange rate movements (weakening USD against GBP and EUR).

Guidance, Outlook, and Risks

Recent Developments: The company presented five-year overall survival data for KIMMTRAK at the AACR 2026 meeting, showing a 16% survival rate versus 8% in the control arm. Two posters regarding brenetafusp and IL7 effects are scheduled for presentation at ASCO 2026.

Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($844.9M combined), along with anticipated revenue, to fund operations for at least twelve months. The company anticipates continuing to incur significant expenses and operating losses in the foreseeable future as it advances clinical programs and expands commercialization.

Risks and Contingencies:

• Regulatory & Clinical: Risks associated with the timing and success of clinical trials for pipeline candidates (brenetafusp, IMC-P115C, etc.) and maintaining regulatory approvals for KIMMTRAK.
• Financial: Dependence on future financing; potential dilution from equity offerings; and exposure to foreign exchange fluctuations.
• Operational: Supply chain disruptions, manufacturing commitments ($20.5M non-cancellable), and the need to recruit and retain skilled personnel.
• Collaboration: Obligations under the Gates Foundation agreement regarding neglected diseases and potential buy-back provisions.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $844.9M in liquid assets against the projected burn rate, given the negative operating cash flow of $13.8M in Q1 2026.
• Debt Conversion: Review the terms of the $402.5M convertible senior notes (maturing 2030, 2.50% coupon) and the potential dilution impact if converted (approx. 5.95M shares).
• Revenue Deductions: Scrutinize the $144.5M in accrued rebates, chargebacks, and returns, which represent a significant liability and rely on management estimates.
• Clinical Milestones: Monitor upcoming data readouts for brenetafusp (PRISM-MEL-301) and other pipeline assets to assess future revenue potential beyond KIMMTRAK.
• Geographic Concentration: Note that 63% of revenue is derived from the U.S. market, exposing the company to U.S.-specific pricing and reimbursement risks.